...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Corp (ZEC) held the shares issued to RVX shareholders in June 2013.

No argument there Koo. There has just been a lot of misunderstanding of RPS's on the Board which could give people a false idea that since there aren't more RPS's being issued that their value to each holder isn't affected. It is as the value of that fixed number keeps being spread among more shares.

Share
New Message
Please login to post a reply